Nur77 Gene Knockout Alters Dopamine Neuron Biochemical Activity and Dopamine Turnover

Biological Psychiatry

Volumn 60, Issue 6, 2006, Pages 538-547

  Gilbert, François ^a   Morissette, Marc ^a   St Hilaire, Michel ^a   Paquet, Brigitte ^a   Rouillard, Claude ^a   Di Paolo, Thérèse ^a   Lévesque, Daniel ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

antipsychotic drug; catechol O methyltransferase (COMT); dopamine D2 autoreceptor; dopamine metabolism; NGFI B; Nurr1; tyrosine hydroxylase (TH)

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; AUTORECEPTOR; CELL NUCLEUS RECEPTOR; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE DERIVATIVE; HALOPERIDOL; NUCLEAR RECEPTOR NUR77; QUINPIROLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG BINDING SITE; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME REPRESSION; FUNCTIONAL PROTEOMICS; HYPERACTIVITY; KNOCKOUT GENE; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOLECULAR DYNAMICS; MOUSE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; RECEPTOR INTRINSIC ACTIVITY; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; CATECHOL O-METHYLTRANSFERASE; CORPUS STRIATUM; DNA-BINDING PROTEINS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; ELECTROCHEMISTRY; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; NEURONS; PROTEIN BINDING; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; TRANSCRIPTION FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 33748754376     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.04.023     Document Type: Article

References (47)

1. Beaudry G., Langlois M.-C., Weppe I., Rouillard C., and Lévesque D. Contrasting patterns and cellular specificity of transcriptional regulation of the nuclear receptor nerve growth factor-inducible B by haloperidol and clozapine in the rat forebrain. J Neurochem 75 (2000) 1694-1702
2. Bhardwaj S.K., Beaudry G., Quirion R., Lévesque D., and Srivastava L.K. Neonatal ventral hippocampus lesion leads to reductions in nerve growth factor inducible-B mRNA in the prefrontal cortex and increased amphetamine response in the nucleus accumbens and dorsal striatum. Neuroscience 122 (2003) 669-676
3. Bilder R.M., Volavka J., Lachman H.M., and Grace A.A. The catechol-O-methyltransferase polymorphism: Relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 29 (2004) 1943-1961
4. 125I]iodophenyl)tropane-2 β-carboxylic acid isopropyl ester. Mol Pharmacol 47 (1995) 779-786
5. Carboni E., and Silvagni A. Dopamine reuptake by norepinephrine neurons: Exception or rule?. Crit Rev Neurobiol 16 (2004) 121-128
6. Cossette M., Parent A., and Lévesque D. Tyrosine hydroxylase-positive neurons intrinsic to the human striatum express the transcription factor Nurr1. Eur J Neurosci 20 (2004) 2089-2095
7. Di Paolo T., Lévesque D., and Daigle M. A physiological dose of progesterone affects rat striatum biogenic amine metabolism. Eur J Pharmacol 125 (1986) 11-16
8. Egan M.F., Chrapusta S., Karoum F., Lipska B.K., and Wyatt R.J. Effects of chronic neuroleptic treatment on dopamine release: insights from studies using 3-methoxytyramine. J Neural Transm 103 (1996) 777-805
9. Egan M.F., Chrapusta S.J., Karoum F., and Wyatt R.J. The effects of acute and chronic haloperidol treatment on dopamine release mediated by the medial forebrain bundle in the striatum and nucleus accumbens. Neuropsychopharmacology 14 (1996) 211-223
10. Eilam D., and Szechtman H. Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur J Pharmacol 161 (1989) 151-157
11. Ethier I., Beaudry G., St-Hilaire M., Milbrandt J., Rouillard C., and Lévesque D. The transcription factor NGFI-B (Nur77) and retinoids play a critical role in acute neuroleptic-induced extrapyramidal effect and striatal neuropeptide gene expression. Neuropsychopharmacology 29 (2004) 335-346
12. Ethier I., Kagechika H., Shudo K., Rouillard C., and Lévesque D. Docosahexaenoic acid reduces haloperidol-induced dyskinesias in mice: Involvement of Nur77 and retinoid receptors. Biol Psychiatry 56 (2004) 522-526
13. Evans R. A transcriptional basis for physiology. Nat Med 10 (2004) 1022-1026
14. Garris P.A., Budygin E.A., Phillips P.E.M., Venton B.J., Robinson D.L., Bergström B.P., et al. A role for presynaptic mechanisms in the actions of nomifensine and haloperidol. Neuroscience 118 (2003) 819-829
15. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., and Karayiorgou M. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 95 (1998) 9991-9996
16. Gronemeyer H., Gustafsson J.A., and Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3 (2004) 950-964
17. Hermanson E., Joseph B., Castro D., Lindqvist E., Aarnisalo P., Wallen A., et al. Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells. Exp Cell Res 288 (2003) 324-334
18. Hung A.C., Huang H.M., Tsay H.J., Lin T.N., Kuo J.S., and Sun S.H. ATP-stimulated c-fos and zif268 mRNA expression is inhibited by chemical hypoxia in a rat brain-derived type 2 astrocyte cell line, RBA-2. J Cell Biochem 77 (2000) 323-332
19. Huotari M., Gogos J.A., Karayiorgou M., Koponen O., Forsberg M., Raasmaja A., et al. Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci 15 (2002) 246-256
20. Iwawaki T., Kohno K., and Kobayashi K. Identification of a potential Nurr1 response element that activates the tyrosine hydroxylase gene promoter in cultured cells. Biochem Biophys Res Commun 274 (2000) 590-595
21. Jonkers N., Sarre S., Ebinger G., and Michotte Y. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat. J Neural Transm 108 (2001) 559-570
22. Karhunen T., Tilgmann C., Ulmanen I., and Panula P. Neuronal and non-neuronal catechol-O-methyltransferase in primary cultures of rat brain cells. Int J Dev Neurosci 13 (1995) 825-834
23. Lee S.L., Wesselschmidt R.L., Linette G.P., Kanagawa O., Russell J.H., and Milbrandt J. Unimpaired thymic and peripheral T cell death in mice lacking the nuclear receptor NGFI-B (Nur77). Science 269 (1995) 532-535
24. 2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl) 183 (2005) 144-153
25. Lindley S.E., She X.H., and Schatzberg A.F. Monoamine oxidase and catechol-O-methyltransferase enzyme activity and gene expression in response to sustained glucocorticoids. Psychoneuroendocrinology 30 (2005) 785-790
26. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. J Biol Chem 193 (1951) 265-275
27. Maheux J., Ethier I., Rouillard C., and Lévesque D. Induction patterns of transcription factors of the Nur family (Nurr1, Nur77 and Nor-1) by typical and atypical antipsychotics in the mouse brain: Implication for their mechanism of action. J Pharmacol Exp Ther 313 (2005) 460-473
28. Maira M., Martens C., Philips A., and Drouin J. Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation. Mol Cell Biol 19 (1999) 7549-7557
29. Mannisto P.T., and Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51 (1999) 593-628
30. Matsumoto M., Weickert C.S., Beltaifa S., Kolachana B., Chen J.S., Hyde T.M., et al. Catechol O-methyltransferase (COMT) mRNA expression in the dorsolateral prefrontal cortex of patients with schizophrenia. Neuropsychopharmacology 28 (2003) 1521-1530
31. Morissette M., and Di Paolo T. Acute effect of 17β-estradiol and lithium on ovariectomized rat brain biogenic amines metabolism. J Psychiat Res 30 (1996) 95-107
32. Nissbrandt H., Sundström E., Jonsson G., Hjorth S., and Carlsson A. Synthesis and release of dopamine in rat brain: comparison between substantia nigra pars compacts, pars reticulata, and striatum. J Neurochem 52 (1989) 1170-1182
33. Olson L., Cheng H., Zetterström R.H., Solomin L., Jansson L., Giménez-Llort L., et al. On CNS repair and protection strategies: novel approaches with implications for spinal cord injury and Parkinson's disease. Brain Res Brain Res Rev 26 (1998) 302-305
34. Paulsen R.F., Granas K., Johnsen H., Rolseth V., and Sterri S. Three related brain nuclear receptors, NGFI-B, Nurr1, and NOR-1, as transcriptional activators. J Mol Neurosci 6 (1995) 249-255
35. Perlmann T., and Jansson L. A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1. Genes Dev 9 (1995) 769-782
36. Philips A., Lesage S., Gingras R., Maira M.-H., Gauthier Y., Hugo P., and Drouin J. Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells. Mol Cell Biol 17 (1997) 5946-5951
37. Sacchetti P., Mitchell T.R., Granneman J.G., and Bannon M.J. Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism. J Neurochem 76 (2001) 1565-1572
38. Sakurada K., Ohshima-Sakurada M., Palmer T.D., and Gage F.H. Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. Development 126 (1999) 4017-4026
39. Schmitz Y., Benoit-Marand M., Gonon F., and Sulzer D. Presynaptic regulation of dopaminergic neurotransmission. J Neurochem 87 (2003) 273-289
40. Sharman D.F. The turnover of catecholamines. In: Pycock C.J., and Taberner P.V. (Eds). Central Neurotransmitter Turnover (1985), Croom Helm, London 20-58
41. St-Hilaire M., Landry É., Lévesque D., and Rouillard C. Denervation and repeated L-DOPA induce a coordinate expression of the transcription factor NGFI-B in striatal projection pathways in hemi-parkinsonian rats. Neurobiol Dis 14 (2003) 98-109
42. St-Hilaire M., Tremblay P.-O., Lévesque D., Barden N., and Rouillard C. Effects of cocaine on c-fos and NGFI-B mRNA expression in transgenic mice underexpressing glucocorticoid receptors. Neuropsychopharmacology 28 (2003) 478-489
43. Werme M., Olson L., and Brené S. NGFI-B and Nor1 mRNAs are upregulated in brain reward pathways by drugs of abuse: Different effects in Fischer and Lewis rats. Mol Brain Res 76 (2000) 18-24
44. Werme M., Ringholm A., Olson L., and Brené S. Differential patterns of induction of NGFI-B, Nor1 and c-fos mRNAs in striatal subregions by haloperidol and clozapine. Brain Res 863 (2000) 112-119
45. Zetterström R.H., Solomin L., Jansson L., Hoffer B.J., Olson L., and Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science 276 (1997) 248-250
46. Zetterström R.H., Williams R., Perlmann T., and Olson L. Cellular expression of the immediate-early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. Mol Brain Res 41 (1996) 111-120
47. Zetterström T., Sharp T., and Ungerstedt U. Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis. Eur J Pharmacol 106 (1984) 27-37